Leads for the treatment of pulmonary hypertension

Bibliography

• Simonneau G, Galie N, Rubin LJ, et al. Clinical classification of pulmonary hypertension. J Am Coll Cardiol 2004;43(12 Suppl S):5S-12S
   PubMed Web of Science ®Google Scholar
• Raiesdana A, Loscalzo J. Pulmonary arterial hypertension. Ann Med 2006;38(2):95-110
   Web of Science ®Google Scholar
• van Wolferen SA, Grunberg K, Vonk Noordegraaf A. Diagnosis and management of pulmonary hypertension over the past 100 years. Respir Med 2007;101(3):389-98
   PubMed Web of Science ®Google Scholar
• McLaughlin VVMD, McGoon MDMD. Pulmonary arterial hypertension. Circulation 2006;114(13):1417-31
   PubMed Web of Science ®Google Scholar
• Naeije R, Huez S. Expert opinion on available options treating pulmonary arterial hypertension. Expert Opin Pharmacother 2007;8(14):2247-65
   PubMed Web of Science ®Google Scholar
• Galie N, Torbicki A, Barst R, et al. Guidelines on diagnosis and treatment of pulmonary arterial hypertension. The task force on diagnosis and treatment of pulmonary arterial hypertension of the European society of cardiology. Eur Heart J 2004;25(24):2243-78
   PubMed Web of Science ®Google Scholar
• Olschewski H. Dana Point: what is new in the diagnosis of pulmonary hypertension? Dtsch Med Wochenschr 2008;133(Suppl 6):S180-2
   Google Scholar
• Machado RD, James V, Southwood M, et al. Investigation of second genetic hits at the BMPR2 locus as a modulator of disease progression in familial pulmonary arterial hypertension. Circulation 2005;111(5):607-13
   PubMedGoogle Scholar
• Yuan JX, Rubin LJ. Pathogenesis of pulmonary arterial hypertension: the need for multiple hits. Circulation 2005;111(5):534-8
   PubMedGoogle Scholar
• Humbert M. Update in pulmonary arterial hypertension 2007. Am J Respir Crit Care Med 2008;177(6):574-9
   PubMed Web of Science ®Google Scholar
• Christman BW, McPherson CD, Newman JH, et al. An imbalance between the excretion of thromboxane and prostacyclin metabolites in pulmonary hypertension. N Engl J Med 1992;327(2):70-5
   PubMed Web of Science ®Google Scholar
• Maruno K, Absood A, Said SI. VIP inhibits basal and histamine-stimulated proliferation of human airway smooth muscle cells. Am J Physiol 1995;268(6 Pt 1):L1047-51
   PubMedGoogle Scholar
• Giaid A, Saleh D. Reduced expression of endothelial nitric oxide synthase in the lungs of patients with pulmonary hypertension. N Engl J Med 1995;333(4):214-21
   PubMed Web of Science ®Google Scholar
• Davenport AP, Maguire JJ. Endothelin Handb Exp Pharmacol 2006;(176 Pt 1):295-329
   Google Scholar
• Herve P, Launay JM, Scrobohaci ML, et al. Increased plasma serotonin in primary pulmonary hypertension. Am J Med 1995;99(3):249-54
   PubMed Web of Science ®Google Scholar
• Tuder RM, Flook BE, Voelkel NF. Increased gene expression for VEGF and the VEGF receptors KDR/Flk and Flt in lungs exposed to acute or to chronic hypoxia. Modulation of gene expression by nitric oxide. J Clin Invest 1995;95(4):1798-807
   PubMed Web of Science ®Google Scholar
• Rai PR, Cool CD, King JA, et al. The cancer paradigm of severe pulmonary arterial hypertension. Am J Respir Crit Care Med 2008;178(6):558-64
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB. Emerging treatments for pulmonary arterial hypertension. Expert Opin Emerg Drugs 2006;11(4):609-19
   PubMedGoogle Scholar
• Barst RJ, Rubin LJ, Long WA, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. The Primary Pulmonary Hypertension Study Group. N Engl J Med 1996;334(5):296-302
   PubMed Web of Science ®Google Scholar
• Kuhn KP, Byrne DW, Arbogast PG, et al. Outcome in 91 consecutive patients with pulmonary arterial hypertension receiving epoprostenol. Am J Respir Crit Care Med 2003;167(4):580-6
   PubMed Web of Science ®Google Scholar
• Rosenzweig EB, Kerstein D, Barst RJ. Long-term prostacyclin for pulmonary hypertension with associated congenital heart defects. Circulation 1999;99(14):1858-65
   PubMed Web of Science ®Google Scholar
• Simonneau G, Barst RJ, Galie N, et al. Continuous subcutaneous infusion of treprostinil, a prostacyclin analogue, in patients with pulmonary arterial hypertension: a double-blind, randomized, placebo-controlled trial. Am J Respir Crit Care Med 2002;165(6):800-4
   PubMed Web of Science ®Google Scholar
• Kaukinen S, Ylitalo P, Pessi T, Vapaatalo H. Hemodynamic effects of iloprost, a prostacyclin analog. Clin Pharmacol Ther 1984;36(4):464-9
   PubMed Web of Science ®Google Scholar
• Hoeper MM, Schwarze M, Ehlerding S, et al. Long-term treatment of primary pulmonary hypertension with aerosolized iloprost, a prostacyclin analogue. N Engl J Med 2000;342(25):1866-70
   PubMed Web of Science ®Google Scholar
• Wensel R, Opitz CF, Ewert R, et al. Effects of iloprost inhalation on exercise capacity and ventilatory efficiency in patients with primary pulmonary hypertension. Circulation 2000;101(20):2388-92
   PubMed Web of Science ®Google Scholar
• Galie N, Manes A, Branzi A. The new clinical trials on pharmacological treatment in pulmonary arterial hypertension. Eur Respir J 2002;20(4):1037-49
   PubMed Web of Science ®Google Scholar
• Okano Y, Yoshioka T, Shimouchi A, et al. Orally active prostacyclin analogue in primary pulmonary hypertension. Lancet 1997;349(9062):1365
   PubMed Web of Science ®Google Scholar
• Barst RJ, McGoon M, McLaughlin V, et al. Beraprost therapy for pulmonary arterial hypertension. J Am Coll Cardiol 2003;41(12):2119-25
   PubMed Web of Science ®Google Scholar
• Ono Pharmaceutical Co, Ltd. Endogenous repair factor production promoters. WO2004032965; 2004
   Google Scholar
• Yamasaki SI, Kawamoto A, Hayashi M, et al. ONO-1301, a novel non-prostanoid prostacyclin mimetic with a potent inhibitory activity against thromboxane synthase. Jpn J Pharmacol 1995;67(Suppl 1):274P
   Google Scholar
• Barst RJ, Langleben D, Frost A. et al. Sitaxsentan therapy for pulmonary arterial hypertension. Am J Respir Crit Care Med 2004;169(4):441-7
   PubMed Web of Science ®Google Scholar
• Rubin LJ, Badesch DB, Barst RJ, et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med 2002;346(12):896-903
   PubMed Web of Science ®Google Scholar
• Boss C, Bolli M, Weller T. Endothelin receptor antagonists: structures, synthesis, selectivity and therapeutic applications. Curr Med Chem 2002;9(3):349-83
   Google Scholar
• Dingemanse J, van Giersbergen PL. Clinical pharmacology of bosentan, a dual endothelin receptor antagonist. Clin Pharmacokinet 2004;43(15):1089-115
   PubMed Web of Science ®Google Scholar
• Channick RN, Simonneau G, Sitbon O, et al. Effects of the dual endothelin-receptor antagonist bosentan in patients with pulmonary hypertension: a randomised placebo-controlled study. Lancet 2001;358(9288):1119-23
   PubMed Web of Science ®Google Scholar
• Dhaun N, Melville V, Kramer W, et al. The pharmacokinetic profile of sitaxsentan, a selective endothelin receptor antagonist, in varying degrees of renal impairment. Br J Clin Pharmacol 2007;64(6):733-7
   Google Scholar
• Wu C, Chan MF, Stavros F, et al. Discovery of TBC11251, a potent, long acting, orally active endothelin receptor-A selective antagonist. J Med Chem 1997;40(11):1690-7
   PubMed Web of Science ®Google Scholar
• Waxman AB. A review of sitaxsentan sodium in patients with pulmonary arterial hypertension. Vasc Health Risk Manag 2007;3(1):151-7
   PubMedGoogle Scholar
• Scott LJ. Sitaxentan: in pulmonary arterial hypertension. Drugs 2007;67(5):761-70; discussion 71-2
   Google Scholar
• Cheng JWM. Ambrisentan for the management of pulmonary arterial hypertension. Clin Ther 2008;30(5):825-33
   PubMed Web of Science ®Google Scholar
• Vatter H, Seifert V. Ambrisentan, a non-peptide endothelin receptor antagonist. Cardiovasc Drug Rev 2006;24(1):63-76
   PubMed Web of Science ®Google Scholar
• Dhaun N, Pollock DM, Goddard J, Webb DJ. Selective and mixed endothelin receptor antagonism in cardiovascular disease. Trends Pharmacol Sci 2007;28(11):573-9
   PubMed Web of Science ®Google Scholar
• Barst RJ, Langleben D, Badesch D, et al. Treatment of pulmonary arterial hypertension with the selective endothelin-A receptor antagonist sitaxsentan. J Am Coll Cardiol 2006;47(10):2049-56
   PubMed Web of Science ®Google Scholar
• Nishida M, Okada Y, Akiyoshi K, et al. Role of endothelin ETB receptor in the pathogenesis of monocrotaline-induced pulmonary hypertension in rats. Eur J Pharmacol 2004;496(1-3):159-65
   PubMed Web of Science ®Google Scholar
• Motte S, McEntee K, Naeije R. Endothelin receptor antagonists. Pharmacol Ther 2006;110(3):386-414
   PubMed Web of Science ®Google Scholar
• Actelion Pharmaceuticals Ltd. Pyrimidine-sulfamides and their use as endothelin receptor antagonist. WO2004050640; 2004
   Google Scholar
• Iglarz M, Binkert C, Morrison K, et al. Pharmacology of macitentan, an orally active tissue-targeting dual endothelin receptor antagonist. J Pharmacol Exp Ther 2008;327(3):736-45
   PubMed Web of Science ®Google Scholar
• Wu C, Decker ER, Blok N, et al. Discovery, modeling, and human pharmacokinetics of N-(2-acetyl-4,6-dimethylphenyl)- 3-(3,4-dimethylisoxazol-5-ylsulfamoyl) thio phene-2-carboxamide (TBC3711), a second generation, ETA selective, and orally bioavailable endothelin antagonist. J Med Chem 2004;47(8):1969-86
   PubMed Web of Science ®Google Scholar
• Ihara M, Noguchi K, Saeki T, et al. Biological profiles of highly potent novel endothelin antagonists selective for the ETA receptor. Life Sci 1992;50(4):247-55
   PubMed Web of Science ®Google Scholar
• Bradbury RH, Bath C, Butlin RJ, et al. New non-peptide endothelin-A receptor antagonists: synthesis, biological properties, and structure-activity relationships of 5-(dimethylamino)-N-pyridyl-, -N-pyrimidinyl-,-N-pyridazinyl-, and -N-pyrazinyl-1-naphthalenesulfonamides. J Med Chem 1997;40(6):996-1004
   Google Scholar
• Raja SG, Danton MD, MacArthur KJ, Pollock JC. Treatment of pulmonary arterial hypertension with sildenafil: from pathophysiology to clinical evidence. J Cardiothorac Vasc Anesth 2006;20(5):722-35
   Google Scholar
• Croom KF, Curran MP, Abman SH, et al. Sildenafil: a review of its use in pulmonary arterial hypertension. Drugs 2008;68(3):383-97
   PubMed Web of Science ®Google Scholar
• Simonneau G, Rubin LJ, Galie N, et al. Addition of sildenafil to long-term intravenous epoprostenol therapy in patients with pulmonary arterial hypertension: a randomized trial. Ann Intern Med 2008;149(8):521-30
   PubMed Web of Science ®Google Scholar
• Naeije R, Huez S. Expert opinion on available options treating pulmonary arterial hypertension. Exp Opin Pharmacother 2007;8(14):2247-65
   PubMed Web of Science ®Google Scholar
• Evgenov OV, Pacher P, Schmidt PM, et al. NO-independent stimulators and activators of soluble guanylate cyclase: discovery and therapeutic potential. Nat Rev Drug Discov 2006;5(9):755-68
   PubMed Web of Science ®Google Scholar
• Bayer Healthcare AG. Carbamate-substituted pyrazolopyridines. WO2003095451; 2003
   Google Scholar
• Bayer Healthcare AG. Use of soluble guanylate cyclase activators for treating acute and chronic lung diseases. WO2007039155; 2007
   Google Scholar
• Frey R, Muck W, Unger S, et al. Single-dose pharmacokinetics, pharmacodynamics, tolerability, and safety of the soluble guanylate cyclase stimulator BAY 63-2521: an ascending-dose study in healthy male volunteers. J Clin Pharmacol 2008;48(8):926-34
   PubMed Web of Science ®Google Scholar
• Straub A, Stasch JP, Alonso-Alija C, et al. NO-independent stimulators of soluble guanylate cyclase. Bioorg Med Chem Lett 2001;11(6):781-4
   PubMed Web of Science ®Google Scholar
• Bayer Healthcare AG. Pyrazolopyridine, indazole, imidazopyridine, imidazopyrimidine, pyrazolopyrazine and pyrazolopyridine derivates as stimulators of guanylate cyclase for cardiovascular disorders. WO2008031513; 2008
   Google Scholar
• Glen R, et al. Activators of soluble guanylate cyclase. WO2001032604; 2001
   Google Scholar
• Nakane M, Kolasa T, Chang R, et al. Acrylamide analog as a novel nitric oxide-independent soluble guanylyl cyclase activator. J Pharmacol Sci 2006;102(2):231-8
   Google Scholar
• Sanofi-aventis Deutschland GmbH. Sulfur substituted sulfonylaminocarboxylic acid N-arylamides, their preparation, their use and pharmaceutical preparations comprising them. WO2000002851; 2000
   Google Scholar
• Sanofi-aventis Deutschland GmbH. Substituted 4-amino-2-aryl-pyrimidines, their production and use and pharmaceutical preparations containing same. WO2000009496; 2000
   Google Scholar
• Bayer Healthcare AG. Heterocyclic compounds with carboxyl isostere groups and their use for the treatment of cardiovascular diseases. WO2007045366; 2007
   Google Scholar
• Bayer Healthcare AG. Tetrazol derivatives and their use for the treatment of cardiovascular diseases. WO2007045370; 2007
   Google Scholar
• Bayer Healthcare AG. Difluorophenol derivatives and their use. WO2007045369; 2007
   Google Scholar
• Bayer Healthcare AG. Dicarboxylic acid derivatives and their use. WO2007045433; 2007
   Google Scholar
• Bayer Healthcare AG. Cyclopropylacetic acid derivatives and use thereof. WO2007045367; 2007
   Google Scholar
• Bayer Healthcare AG. Novel aza-bicyclic compounds and their use as stimulators of soluble guanylate cyclase. WO2008061657; 2008
   Google Scholar
• Evgenov OV, Kohane DS, Bloch KD, et al. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med 2007;176(11):1138-45
   PubMed Web of Science ®Google Scholar
• Eddahibi S, Adnot S. From functional to genetic studies of a candidate gene for pulmonary hypertension: any point? Am J Respir Crit Care Med 2006;173(7):693-4
   Google Scholar
• Long L, MacLean MR, Jeffery TK, et al. Serotonin increases susceptibility to pulmonary hypertension in BMPR2-deficient mice. Circ Res 2006;98(6):818-27
   PubMed Web of Science ®Google Scholar
• Kawut SM, Horn EM, Berekashvili KK, et al. Selective serotonin reuptake inhibitor use and outcomes in pulmonary arterial hypertension. Pulm Pharmacol Ther 2006;19(5):370-4
   PubMed Web of Science ®Google Scholar
• Epix Pharmaceuticals, Inc. New piperidinylamino-thieno[2,3-d]pyrimidine compounds. WO2004089312; 2004
   Google Scholar
• Predix Pharmaceuticals Holdings, Inc. Piperidinylamino-thieno[2,3-d] pyrimidine compounds. US7030240; 2006
   Google Scholar
• Gilead Colorado, Inc. 5-HT2 receptors modulators, their pharmaceuticals compositions and their use for the treatment of cardiovascular and muscle diseases. WO2005063712; 2005
   Google Scholar
• Gilead Colorado, Inc. Modulation of 5-HT2 receptors as a treatment for cardiovascular diseases. WO2005063220; 2005
   Google Scholar
• Pfizer Products Inc. Aralkyl and aralkylidene heterocyclic lactams and with affinity for 5-HT1 receptors. WO2005061491; 2005
   Google Scholar
• Pfizer Products Inc. Novel piperazinone derivatives. WO2007057742; 2007
   Google Scholar
• Boehringer Ingelheim Pharma GmbH & Co. KG. Benzimidazolone derivates in the treatment of pulmonary arterial hypertension. WO2008061968; 2008
   Google Scholar
• Ito M, Nakano T, Erdodi F, Hartshorne DJ. Myosin phosphatase: structure, regulation and function. Mol Cell Biochem 2004;259(1-2):197-209
   PubMed Web of Science ®Google Scholar
• Abe K, Shimokawa H, Morikawa K, et al. Long-term treatment with a Rho-kinase inhibitor improves monocrotaline-induced fatal pulmonary hypertension in rats. Circ Res 2004;94(3):385-93
   PubMed Web of Science ®Google Scholar
• Fagan KA, Oka M, Bauer NR, et al. Attenuation of acute hypoxic pulmonary vasoconstriction and hypoxic pulmonary hypertension in mice by inhibition of Rho-kinase. Am J Physiol Lung Cell Mol Physiol 2004;287(4):L656-64
   PubMed Web of Science ®Google Scholar
• Fukumoto Y, Matoba T, Ito A, et al. Acute vasodilator effects of a Rho-kinase inhibitor, fasudil, in patients with severe pulmonary hypertension. Heart 2005;91(3):391-2
   PubMed Web of Science ®Google Scholar
• Rho family antagonists and their use to block inhibition of neurite outgrowth. WO1999023113; 1999
   Google Scholar
• Nagaoka T, Fagan KA, Gebb SA, et al. Inhaled Rho kinase inhibitors are potent and selective vasodilators in rat pulmonary hypertension. Am J Respir Crit Care Med 2005;171(5):494-9
   PubMed Web of Science ®Google Scholar
• D Western Therapeutics Institute, Inc. 4-Bromoisoquinoline derivative and pharmaceutical preparation comprising the same. WO2006115244; 2006
   Google Scholar
• D Western Therapeutics Institute, Inc. Highly selective Rho-kinase inhibitor. WO2006115247; 2006
   Google Scholar
• D Western Therapeutics Institute, Inc. 4-Ethynylisoquinoline derivative and pharmaceutical preparation comprising the same. WO2006115245; 2006
   Google Scholar
• Sanofi-aventis Deutschland GmbH. Isoquinoline derivatives as inhibitors of Rho-kinase. WO2007000240; 2007
   Google Scholar
• Sanofi-aventis Deutschland GmbH. Cyclohexylamin isoquinolone derivatives as Rho-kinase inhibitors. WO2007012422; 2007
   Google Scholar
• Sanofi-aventis Deutschland GmbH. Piperidinyl-substituted isoquinolone derivatives as Rho-kinase inhibitors. WO2007012421; 2007
   Google Scholar
• Borchardt AJ, et al. Heteroaryl inhibitors of Rho kinase. WO2008011557; 2008
   Google Scholar
• Kahraman M, et al. Benzothiphene inhibitors of Rho kinase. WO2008011560; 2008
   Google Scholar
• Boehringer Ingelheim Pharma GmbH & Co. KG. Rho kinase inhibitors. WO2008036540; 2008
   Google Scholar
• Boehringer Ingelheim Pharma GmbH & Co. KG. Rho kinase inhibitors. WO2008086047; 2008
   Google Scholar
• Schermuly RT, Dony E, Ghofrani HA, et al. Reversal of experimental pulmonary hypertension by PDGF inhibition. J Clin Invest 2005;115(10):2811-21
   PubMed Web of Science ®Google Scholar
• Klein M, Schermuly RT, Ellinghaus P, et al. Combined tyrosine and serine/threonine kinase inhibition by sorafenib prevents progression of experimental pulmonary hypertension and myocardial remodeling. Circulation 2008;118(20):2081-90
   PubMed Web of Science ®Google Scholar
• Bayer Corporation. ω-carboxy aryl substituted phenyl ureas as p38 kinase inhibitors. WO2000041698; 2000
   Google Scholar
• Atallah E, Durand JB, Kantarjian H, Cortes J. Congestive heart failure is a rare event in patients receiving imatinib therapy. Blood 2007;110(4):1233-7
   PubMed Web of Science ®Google Scholar
• Signal Pharmaceuticals LLC (d/b/a Celgene Research San Diego). Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith. WO2006076595; 2006
   Google Scholar
• Albers RJ, et al. Haloaryl substituted aminopurines, compositions thereof, and methods of treatment therewith. US2007060598; 2007
   Google Scholar
• Signal Pharmaceuticals LLC (d/b/a Celgene Research San Diego). Methods of treatment and prevention using haloaryl substituted aminopurines. US2008021048; 2008
   Google Scholar
• IRM LLC. Compositions and methods for modulating c-kit and PDGFR receptors. WO2008051757; 2008
   Google Scholar
• IRM LLC. Pyrimidine derivatives and compositions as c-kit and PDGFR kinase inhibitors. WO2008137605; 2008
   Google Scholar
• IRM LLC. Compounds and compositions as c-kit and PDGFR kinase inhibitors. WO2008137770; 2008
   Google Scholar
• IRM LLC. Compounds and compositions as c-kit and PDGFR kinase inhibitors. WO2008137794; 2008
   Google Scholar
• Novartis AG. Heterocyclic compounds as antiinflammatory agents. WO2008052734; 2008
   Google Scholar
• Said SI, Hamidi SA, Dickman KG, et al. Moderate pulmonary arterial hypertension in male mice lacking the vasoactive intestinal peptide gene. Circulation 2007;115(10):1260-8
   PubMed Web of Science ®Google Scholar
• Busto R, Prieto JC, Bodega G, et al. Immunohistochemical localization and distribution of VIP/PACAP receptors in human lung. Peptides 2000;21(2):265-9
   PubMed Web of Science ®Google Scholar
• Petkov V, Mosgoeller W, Ziesche R, et al. Vasoactive intestinal peptide as a new drug for treatment of primary pulmonary hypertension. J Clin Invest 2003;111(9):1339-46
   PubMed Web of Science ®Google Scholar
• F.Hoffmann-La Roche AG. Analogs of vasoactive intestinal peptide. WO2008003612; 2008
   Google Scholar
• Forbes Medi-Tech (Research) Inc. Vasoactive intestinal polypeptide pharmaceuticals. US2008214440; 2008
   Google Scholar
• Li M, Li Z, Sun X. Statins suppress MMP2 secretion via inactivation of RhoA/ROCK pathway in pulmonary vascular smooth muscles cells. Eur J Pharmacol 2008;591(1-3):219-23
   PubMed Web of Science ®Google Scholar
• Sun X, Ku DD. Rosuvastatin provides pleiotropic protection against pulmonary hypertension, right ventricular hypertrophy, and coronary endothelial dysfunction in rats. Am J Physiol Heart Circ Physiol 2008;294(2):H801-9
   PubMed Web of Science ®Google Scholar
• Zaidi SH, You XM, Ciura S, et al. Overexpression of the serine elastase inhibitor elafin protects transgenic mice from hypoxic pulmonary hypertension. Circulation 2002;105(4):516-21
   PubMed Web of Science ®Google Scholar
• AstraZeneca AB. 2-Pyrazinone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. WO2007129963; 2007
   Google Scholar
• AstraZeneca AB. 2-Pyridone derivatives for the treatment of disease or condition in which inhibition of neutrophil elastase activity is beneficial. WO2007129962; 2007
   Google Scholar
• Bayer Healthcare AG. The use of 1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension. WO2008003412; 2008
   Google Scholar
• AstraZeneca UK Ltd. Dihydropyridones as elastase inhibitors. WO2008104752; 2008
   Google Scholar
• Yuan JX, Aldinger AM, Juhaszova M, et al. Dysfunctional voltage-gated K+ channels in pulmonary artery smooth muscle cells of patients with primary pulmonary hypertension. Circulation 1998;98(14):1400-6
   PubMed Web of Science ®Google Scholar
• Badesch DB, Abman SH, Simonneau G, et al. Medical therapy for pulmonary arterial hypertension: updated ACCP evidence-based clinical practice guidelines. Chest 2007;131(6):1917-28
   PubMed Web of Science ®Google Scholar